Tumor-driven angiogenesis is a vital process in which the tumor stimulates the formation of new vessels of blood to sustain its rapid expansion, invasion as well as metastasis. The method leverages several pro-angiogenic substances, including the enzyme thymidine phosphorylase (TP), platelet drive growth factor (PDGF), and vascular endothelial growth factor (VEGF). The TP, also known as platelet-derived endothelial cell growth factor, is a proteolytic enzyme considered pivotal in tumor-driven angiogenesis. Its overexpression is linked with an aggressive malignancy, enhanced vascularization, and bad prognosis in various cancers. Thymidine undergoes reversible phosphorylation by TP, which produces thymine and 2-deoxy-D-ribose-1-phoshate. This metabolite, 2-deoxy-D-ribose, acts as a potent angiogenic molecule by stimulating proliferation, endothelial cell migration, and tube formation, thereby promoting the development of new vessels of blood. TP influences the tumor microenvironment by modulating extracellular matrix remodeling and recruiting stromal and immune cells, further facilitating tumor progression. In several cancer types, TP is upregulated and contributes to tumor survival by preventing apoptosis, enhancing hypoxia resistance and synergizing with other angiogenic factors, like VEGF. It also plays a crucial role in promoting vascular network that provides a route for cancer cells to spread to distant sites. The critical improvement in TP in these processes has led to its recognition as a target for anti-angiogenic cancer therapies. Integrating TP-focused diagnostics and therapies into existing oncology research, the precision, effectiveness, and efficiency can be improved in cancer management. This approach aligns with modern health management goals, including personalized medicine, early interventions, and reduced healthcare costs through targeted therapies.